Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors

Inclusion Criteria:

* Aged at least 18 years old;
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~2;
* Patients must have histological or cytological confirmation of advanced solid tumors that is refractory to standard therapy or for which there is no standard available therapy;
* Predicted life expectancy ≥3 months;
* Patients must have adequate organ and marrow function;
* Patients at reproductive age should take adequate contraceptive measures while on study drug and for 6 months following the last dose of study drug.
* Patients should have the ability and willingness to comply with the study and follow up. And patients must be able to provide written informed consent.

Exclusion Criteria:

* Patients who have experienced a Grade 3 or higher toxicity related to prior immunotherapy.
* Patients who are still receive anti-tumor therapy such as radiotherapy, chemotherapy, targeted therapy, endocrine therapy, or other clinical trials from 4 weeks prior to the first dose, or patients who have not recovered from previous toxicity to level 1.
* Women who are pregnant or breast feeding
* Patients who are drug-dependent or have a history of substance abuse or psychonosema history.
* Have been vaccinated within 4 weeks of study dosing, with the exception of licensed intranasal or intramuscular influenza vaccine during study
* Prior allogeneic bone marrow transplantation or prior solid organ transplantation
* Positive laboratory test for HBsAg with HBV DNA ≥ 100 IU/mL, or positive laboratory test for HCV.
* Prior treatment with immune checkpoint inhibitors, immunomodulatory mAbs, and/or mAb-derived therapies is allowed provided that at least 3 months or 5 half-lives of the drug, whichever is longer, have elapsed from the last dose.
* Uncontrolled concurrent illness.
* Major surgery procedure (excluding diagnostic surgery) within 4 weeks of the first dose of study drug.
* Patients with a history of treated CNS metastases.
* Other psychiatric illness/social situations that would limit compliance with the study requirements decided by the investigator.